Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-03-08
2011-03-08
Wen, Sharon (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S130100, C424S145100, C530S387100, C530S387900, C530S388240
Reexamination Certificate
active
07901679
ABSTRACT:
Provided are humanized monoclonal antibodies, and antigen-binding portions thereof, which bind acylated and unacylated human ghrelin. Such antibodies are useful for neutralizing ghrelin activity and treating disorders in which ghrelin activity is detrimental, including obesity and related disorders, and various cancers.
REFERENCES:
patent: WO 01/78335 (2001-10-01), None
patent: WO 2005/016951 (2005-02-01), None
patent: WO 2005/026211 (2005-03-01), None
patent: WO 2006/019577 (2006-02-01), None
Wren et al., Ghrelin Causes Hyperphagia and Obesity in Rats. Diabetes, Nov. 2001, vol. 50, pp. 2540-2547.
Cummings et al., Elevated Plasma Ghrelin Levels in Prader-Willi Syndrome. Nature Medicine, Jul. 2002, vol. 8, pp. 643-644.
Moran et al., Ghrelin and Measures of Satiety Are Altered in Polycystic Ovary Syndrome But Not Differentially Affected by Diet Composition. The Journal of Clinical Endocrinology and Metabolism, Jul. 2004, vol. 89, pp. 3337-3344.
Cigaina et al., Plasma Ghrelin and Gastric Pacing in Morbidly Obese Patients. Metabolism Clinical and Experimental, 2007, vol. 56, pp. 1017-1021.
Kusaka et al., Metformin, But Not Pioglitazone, decreases Postchallenge Plasma Ghrelin Levels in Type 2 Diabetic Patients: A Possible Role in Weight Stability? Diabetes, Obesity and Metabolism, Published Online: Mar. 18, 2008, pp. 1-8.
Bednarek, et al., “Structure-function studies on the new growth hormone-releasing peptide, ghrelin: Minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a,”Journal of Medicinal Chemistry43(23):4370-4376 (2000).
Davies, et al., “Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding,”Immunotechnology, 2(3):169-179.
Gaytan, et al. “Immunolocalization of Ghrelin and Its Functional Receptor, the Type 1A Growth Hormone Secretagogue Receptor, in the Cyclic Human Ovary,”Journal of Clinical Endocrinology and Metabolism, 88(2):879-887 (2003).
Helmling, et al., “The Promise of Ghrelin Antagonism in Obesity Treatment,”Drug News and Perspectives, 19(1):13-20 (2006).
Holt, et al., “Domain antibodies: proteins for therapy,”Trends in Biotechnology, 21(11):484-490 (2003).
Hosoda, et al., “Structural divergence of human ghrelin identification of multiple ghrelin-derived molecules produced by post-translational processing,”Journal of Biological Chemistry, 278(1):64-70 (2003).
Murakami, et al., “Role for central ghrelin in food intake and secretion profile of stomach ghrelin in rats,”Journal of Endocrinology174(2):283-288 (2002).
Murata, et al., “Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells, ”Journal of Biological Chemistry277(7):5667-5674 (2002).
Yoshihara, et al., “Ghrelin: A Novel Peptide for Growth Hormone Release and Feeding Regulation,”Current Opinion in Clinical Nutrition and Metabolic Care, 5(4):391-395 (2002).
Marquis David Matthew
Smith Eric Michael
Subramaniam Danise Rogers
Witcher Derrick Ryan
Castetter Andrea M.
Eli Lilly and Company
Wen Sharon
LandOfFree
Humanized anti-ghrelin antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized anti-ghrelin antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized anti-ghrelin antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2654943